Xtant Medical

INVESTORS

HomeInvestors

INVESTORS

Click here for Webcast
Xtant Medical First Quarter 2024 Financial Results
 05/15/24  4:30 PM EDT

Corporate Profile

Xtant Medical Holdings, Inc. (NYSE MKT: XTNT) develops, manufactures and markets regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries.

 

 

 

Stock Quote

(Common Stock)
Price
Change (%)
Volume
Data as of  

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Chart

Recent News

Date Title  
Toggle Summary Xtant Medical Reports First Quarter 2024 Revenue Growth of 55% and Raises Full Year 2024 Revenue Guidance
Expects Revenue for Full Year 2024 of $116 Million to $120 Million BELGRADE, MT, May 15, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported financial and
Toggle Summary Xtant Medical to Issue First Quarter 2024 Financial Results on May 15, 2024
BELGRADE, Mont. , May 13, 2024 -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced that it will release its financial results for the first quarter ended March 31, 2024, after
Toggle Summary Xtant Medical Announces Launch of SimpliGraft™ and SimpliMax™ for Chronic and Acute Wounds
BELGRADE, Mont. , April 30, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the full commercial launch of two amniotic membrane allografts,
Toggle Summary Xtant Medical Announces Record Full Year 2023 Revenue of $91.3 Million
Establishes Full Year 2024 Revenue Guidance of $112 Million - $116 Million BELGRADE, Mont. , April 01, 2024 (GLOBE NEWSWIRE) -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today reported
More
Upcoming Events
There are currently no events scheduled.
More

Receive Email Alerts

Sign up to receive email alerts whenever Xtant Medical Holdings Inc posts new information to the site. Just enter your email address and click Submit.